(HROW) Harrow Health - Overview
Stock: Eye, Gel, Drops, Steroid, Antibiotic
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 65.8% |
| Relative Tail Risk | -14.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.92 |
| Alpha | 32.02 |
| Character TTM | |
|---|---|
| Beta | 1.478 |
| Beta Downside | 1.276 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.15% |
| CAGR/Max DD | 0.52 |
Description: HROW Harrow Health January 19, 2026
Harrow, Inc. (NASDAQ:HROW) is an ophthalmic-focused pharmaceutical company that discovers, develops, and commercializes a broad portfolio of eye-care products, ranging from compounded medications (ImprimisRx) to FDA-approved drops, gels, and injectable therapies such as IHEEZO, VIGAMOX, TRIESENCE, and NATACYN. The firm rebranded from Harrow Health, Inc. to Harrow, Inc. in September 2023 and is headquartered in Nashville, Tennessee.
As of the latest 10-Q (Q3 2024), Harrow reported $68 million in total revenue, with roughly 55 % generated from its flagship products VIGAMOX and TRIESENCE, which benefit from strong Medicare Part B reimbursement trends. The global ophthalmic market is projected to grow at a CAGR of 5.2 % through 2030, driven by an aging population and increasing prevalence of cataract and diabetic retinopathy-key macro drivers that could expand demand for Harrow’s anti-inflammatory and antimicrobial eye drops. However, the company’s reliance on a limited number of high-margin products introduces concentration risk, and generic competition in the steroid-eye-drop segment could pressure margins if patent expirations accelerate.
For a deeper dive into Harrow’s valuation assumptions and how they compare to sector peers, you may find ValueRay’s analytical framework useful.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -4.99m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.06 > 0.02 and ΔFCF/TA -6.50 > 1.0 |
| NWC/Revenue: 44.87% < 20% (prev 30.78%; Δ 14.10% < -1%) |
| CFO/TA 0.05 > 3% & CFO 17.7m > Net Income -4.99m |
| Net Debt (177.6m) to EBITDA (38.5m): 4.62 < 3 |
| Current Ratio: 2.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (38.9m) vs 12m ago 8.89% < -2% |
| Gross Margin: 74.56% > 18% (prev 0.73%; Δ 7384 % > 0.5%) |
| Asset Turnover: 69.98% > 50% (prev 48.11%; Δ 21.87% > 0%) |
| Interest Coverage Ratio: 0.80 > 6 (EBITDA TTM 38.5m / Interest Expense TTM 25.4m) |
Altman Z'' 0.40
| A: 0.31 (Total Current Assets 177.6m - Total Current Liabilities 65.4m) / Total Assets 363.1m |
| B: -0.45 (Retained Earnings -163.2m / Total Assets 363.1m) |
| C: 0.06 (EBIT TTM 20.4m / Avg Total Assets 357.3m) |
| D: -0.52 (Book Value of Equity -163.1m / Total Liabilities 316.4m) |
| Altman-Z'' Score: 0.40 = B |
Beneish M -2.86
| DSRI: 0.98 (Receivables 77.8m/54.0m, Revenue 250.0m/169.1m) |
| GMI: 0.97 (GM 74.56% / 72.56%) |
| AQI: 0.88 (AQ_t 0.48 / AQ_t-1 0.54) |
| SGI: 1.48 (Revenue 250.0m / 169.1m) |
| TATA: -0.06 (NI -4.99m - CFO 17.7m) / TA 363.1m) |
| Beneish M-Score: -2.86 (Cap -4..+1) = A |
What is the price of HROW shares?
Over the past week, the price has changed by +15.58%, over one month by -11.55%, over three months by +37.40% and over the past year by +52.45%.
Is HROW a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the HROW price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 70.6 | 49.3% |
| Analysts Target Price | 70.6 | 49.3% |
| ValueRay Target Price | 63.7 | 34.5% |
HROW Fundamental Data Overview February 02, 2026
P/S = 6.0642
P/B = 32.251
Revenue TTM = 250.0m USD
EBIT TTM = 20.4m USD
EBITDA TTM = 38.5m USD
Long Term Debt = 242.9m USD (from longTermDebt, last quarter)
Short Term Debt = 859.0k USD (from shortTermDebt, last quarter)
Debt = 251.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 177.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.69b USD (1.52b + Debt 251.9m - CCE 74.3m)
Interest Coverage Ratio = 0.80 (Ebit TTM 20.4m / Interest Expense TTM 25.4m)
EV/FCF = -82.73x (Enterprise Value 1.69b / FCF TTM -20.5m)
FCF Yield = -1.21% (FCF TTM -20.5m / Enterprise Value 1.69b)
FCF Margin = -8.19% (FCF TTM -20.5m / Revenue TTM 250.0m)
Net Margin = -1.99% (Net Income TTM -4.99m / Revenue TTM 250.0m)
Gross Margin = 74.56% ((Revenue TTM 250.0m - Cost of Revenue TTM 63.6m) / Revenue TTM)
Gross Margin QoQ = 75.28% (prev 74.54%)
Tobins Q-Ratio = 4.67 (Enterprise Value 1.69b / Total Assets 363.1m)
Interest Expense / Debt = 2.40% (Interest Expense 6.04m / Debt 251.9m)
Taxrate = 0.0% (0.0 / 1.02m)
NOPAT = 20.4m (EBIT 20.4m * (1 - 0.00%))
Current Ratio = 2.72 (Total Current Assets 177.6m / Total Current Liabilities 65.4m)
Debt / Equity = 5.36 (Debt 251.9m / totalStockholderEquity, last quarter 47.0m)
Debt / EBITDA = 4.62 (Net Debt 177.6m / EBITDA 38.5m)
Debt / FCF = -8.67 (negative FCF - burning cash) (Net Debt 177.6m / FCF TTM -20.5m)
Total Stockholder Equity = 55.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.40% (Net Income -4.99m / Total Assets 363.1m)
RoE = -8.96% (Net Income TTM -4.99m / Total Stockholder Equity 55.7m)
RoCE = 6.83% (EBIT 20.4m / Capital Employed (Equity 55.7m + L.T.Debt 242.9m))
RoIC = 7.23% (NOPAT 20.4m / Invested Capital 282.0m)
WACC = 10.08% (E(1.52b)/V(1.77b) * Re(11.36%) + D(251.9m)/V(1.77b) * Rd(2.40%) * (1-Tc(0.0)))
Discount Rate = 11.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.86%
Fair Price DCF = unknown (Cash Flow -20.5m)
EPS Correlation: 36.22 | EPS CAGR: -1.91% | SUE: -2.27 | # QB: 0
Revenue Correlation: 96.12 | Revenue CAGR: 40.18% | SUE: -0.41 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.10 | Chg30d=-0.140 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=2.19 | Chg30d=-0.183 | Revisions Net=-1 | Growth EPS=+254.6% | Growth Revenue=+42.2%